Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 2/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | CTSL | P07711 | 1/20 | 0.34 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.32 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.32 |
| ▸ | RELA | Q04206 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31664493 | 0.87 | MEN1 (0.51) | MEN1KMT2AALDH1A1TSHRBTK | |
| SCHEMBL30747447 | 0.83 | BTK (0.50) | MEN1KMT2ABTKMAOBMAOA | |
| SCHEMBL29213916 | 0.82 | MEN1 (0.47) | MEN1KMT2AALDH1A1TSHRBTK | |
| SCHEMBL31601194 | 0.82 | MEN1 (0.47) | MEN1KMT2AALDH1A1TSHRBTK | |
| SCHEMBL22645691 | 0.82 | MEN1 (0.47) | MEN1KMT2AALDH1A1TSHRBTK | |
| SCHEMBL23036704 | 0.82 | MEN1 (0.47) | MEN1KMT2AALDH1A1TSHRBTK | |
| SCHEMBL30747433 | 0.82 | MEN1 (0.47) | MEN1KMT2AALDH1A1TSHRBTK | |
| SCHEMBL22645692 | 0.82 | MEN1 (0.47) | MEN1KMT2AALDH1A1TSHRBTK | |
| SCHEMBL11888288 | 0.81 | ALDH1A1 (0.47) | MEN1KMT2AALDH1A1TSHRBTK | |
| SCHEMBL13920525 | 0.80 | KMT2A (0.52) | MEN1KMT2AALDH1A1TSHRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-10-09 | — | — | US | disclosed |
| EP-4522583-A2 | PI3K ALPHA INHIBITORS AND METHODS OF USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| CN-119486992-A | PI3K alpha inhibitors and methods of use thereof | 传达治疗有限公司 | 2025-02-18 | — | — | CN | disclosed |
| WO-2023220131-A2 | PI3Kα INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250313524-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CA, PIK3CB, PIK3CD | MEN1 3701/4885KMT2A 2974/4885ALDH1A1 3698/4885 |
| US-20260035335-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | PIK3CD, PIK3CG, PIK3CB | MEN1 3966/4885KMT2A 3086/4885ALDH1A1 4597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.